Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex

NCT00532961 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammation

Interventions

DRUG: Loteprednol etabonate 0.5% and tobramycin 0.3%
DRUG: Dexamethasone 0.1% and tobramycin 0.3%

Sponsor

Bausch & Lomb Incorporated